Pfizer on Thursday said it is moving forward with a once-daily weight loss pill, danuglipron, after getting promising data from an early-stage trial, a milestone for the pharma giant hoping to enter the lucrative obesity drug market and compete with popular weight loss injections Wegovy and Zepbound.
Key Facts
Pfizer said it had evaluated several once-daily formulations of danuglipron and selected its preferred one to move forward to mid-stage trials with.
2.The pharma giant said it had seen “encouraging” data from an ongoing early-stage trial and had identified the candidate with “the most favorable profile.”
3. According to an entry on a federal database of clinical trials, Pfizer tested four different formulations of the once-daily pill in the early-stage trial of 20 people, all of whom were healthy adults ages 18 and over.
The New York-based drugmaker said it will figure out the optimal dose for the pill during the second half of 2024 and will study multiple different options.
“We believe a once-daily formulation has the potential to have a competitive profile in the oral GLP-1 space,” said Pfizer’s chief scientific officer and president for research and development, Mikael Dolsten" taken from Robert Hart
Forbes Staff
This would be an incredible step forward in the weight-loss battle if Pfizer brings this pill to market. All of the literature has been promising. It will only extend the landscape of weight loss forwarding a new era in American health.
Dr. B
Comments